According to the Daily Mail, AstraZeneca (AZN) may be planning to launch a cash bid for Amarin (AMRN). The Mail says other larger pharmaceutical companies, like Merck (MRK), Eli Lilly (LLY), Abbott (ABT) and Pfizer (PFE), "would love to get their hands" on Amarin for Vascepa.
The flap over Apple’s corporate tax strategy might sound like a snoozer, until you consider who makes up the difference …